Natera, Inc. (NTRA) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations.
Is Natera, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, Natera, Inc. (NTRA) trades at $424.42 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Natera, Inc.
Market cap $61B · 52 weeks $183 – $426 (0 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS $-0.28 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/Sales 17.8× (no earnings).
- Business: ROIC −10 % (weak).
- Balance sheet: Net debt/EBITDA 3.9× (fragile).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 1 of 4 pass
- ROIC −10.0 %, fails.
- Net debt / EBITDA 3.9×, fails.
- Gross margin 64.8 %, borderline.
- R&D / Revenue 27.1 %, passes.
Against its peers (reference peers) — Natera, Inc.: P/E —; EV/EBITDA —; ROIC -10.0 %; $61.2B. BillionToOne, Inc. (P/E 184×; EV/EBITDA 99.1×; ROIC 6.3 %; $5.4B), Veracyte, Inc. (P/E 35.9×; EV/EBITDA 29.1×; ROIC 6.7 %; $4.0B), Agilent Technologies, Inc. (P/E 35.7×; EV/EBITDA 25.5×; ROIC 11.9 %; $51.2B).
Profitability
| Return on Equity | -11.73% |
| Return on Invested Capital | -10.02% |
| Return on Assets | -7.24% |
| Gross Margin | 65.30% |
| Operating Margin | -10.70% |
| Net Margin | -7.11% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 3.00 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 23.09 |
Price Performance
| 1 month | +2.39% |
| 3 months | +58.51% |
| Year-to-date | +85.26% |
| 1 year | +120.12% |
| 3 years | +1030.28% |
| 5 years | +270.45% |
| 10 years | +4904.95% |
Related companies: BLLN · VCYT · TMO · 0R0H.L · DHR · 0R2B.L · A · 0HAV.L
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NTRA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks